Has Yifan Pharmaceuticals’ Vorinostat been approved?

Vorinostat (Vorinostat) produced by Yifan Pharmaceuticals may still be in clinical research and has not yet been approved for marketing. The original drug of Vorinostat is not currently on the market in China. Vorinostat was the first histone deacetylase inhibitor approved by the U.S. Food and Drug Administration (FDA) in October 2006 for the treatment of cutaneous T-cell lymphoma (CTCL), but it also failed to demonstrate efficacy in the treatment of acute myeloid leukemia in phase II studies. Vorinostat is a drug currently under investigation for patients with cutaneous T-cell lymphoma (CTCL), a type of skin cancer, that may be used when the disease persists, worsens, or recurs during or after treatment with other drugs.